Patents by Inventor Robin Barbour

Robin Barbour has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9605056
    Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: March 28, 2017
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar
  • Publication number: 20160031976
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: March 12, 2014
    Publication date: February 4, 2016
    Applicant: Prothena Biosciences Limited
    Inventors: Peter Seubert, Philip James Dolan, III, Yue Liu, Robin Barbour
  • Publication number: 20150259404
    Abstract: The invention provides monoclonal antibody 5Cl and related antibodies. The 5Cl antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).
    Type: Application
    Filed: October 8, 2013
    Publication date: September 17, 2015
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar
  • Publication number: 20150259408
    Abstract: The invention provides antibodies that specifically bind to the LG4-5 modules of the G domain of laminin ?4. The antibodies can preferentially stain cancer or tumor cells or tissue. The antibodies can be used for detecting cancer, evaluating the efficacy of a cancer therapy, treating cancer, and treating obesity or obesity-related diseases, among other applications.
    Type: Application
    Filed: March 12, 2015
    Publication date: September 17, 2015
    Inventors: Stephen Jed Tam, Yue Liu, Robin Barbour, Theodore Yednock
  • Publication number: 20150191541
    Abstract: The invention provides monoclonal antibody 8A9 and related antibodies. The 8A9 antibody binds to an epitope within residues 1-10 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.
    Type: Application
    Filed: December 5, 2014
    Publication date: July 9, 2015
    Inventors: Robin Barbour, Tarlochan S. Nijjar
  • Publication number: 20150110777
    Abstract: The invention provides monoclonal antibody 6B8 and related antibodies. The 6B8 antibody binds to an epitope within residues 3-12 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.
    Type: Application
    Filed: July 11, 2014
    Publication date: April 23, 2015
    Inventors: Robin Barbour, Yue Liu
  • Publication number: 20150110776
    Abstract: The invention provides monoclonal antibody 3H6 and related antibodies. The 3H6 antibody binds to an epitope within residues 28-36 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.
    Type: Application
    Filed: July 11, 2014
    Publication date: April 23, 2015
    Inventors: Robin Barbour, Tarlochan S. Nijjar
  • Publication number: 20140348843
    Abstract: The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases.
    Type: Application
    Filed: May 28, 2014
    Publication date: November 27, 2014
    Applicant: NEOTOPE BIOSCIENCES LIMITED
    Inventors: Dale B. Schenk, Tarlochan S. Nijjar, Philip W. Payne, Robin Barbour
  • Publication number: 20140186371
    Abstract: The invention provides antibodies that preferentially bind to iC3b relative to C3b. These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of diseases associated with deposits of the fragment.
    Type: Application
    Filed: April 6, 2012
    Publication date: July 3, 2014
    Inventors: Guriqbal S. Basi, Robin Barbour
  • Patent number: 8741298
    Abstract: The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: June 3, 2014
    Assignee: Neotope Biosciences Limited
    Inventors: Dale B. Schenk, Tarlochan S. Nijjar, Philip W. Payne, Robin Barbour
  • Publication number: 20140127131
    Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).
    Type: Application
    Filed: October 8, 2013
    Publication date: May 8, 2014
    Inventors: ROBIN BARBOUR, KATE DORA GAMES THIEL, TARLOCHAN S. NIJJAR
  • Publication number: 20140127225
    Abstract: The invention provides antibodies that preferentially bind to iC3b relative to C3b. These antibodies find use in treatment and prophylaxis of a variety of diseases associated with deposits of the fragment.
    Type: Application
    Filed: October 7, 2013
    Publication date: May 8, 2014
    Applicant: Neotope Biosciences Limited
    Inventors: Guriqbal S. Basi, Robin Barbour, Yue Liu
  • Patent number: 8673593
    Abstract: The invention provides methods for detecting alpha-synuclein. The invention also identifies preferred epitopes of alpha synuclein for use in such detection, and provides antibodies specifically binding to such epitopes.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: March 18, 2014
    Assignee: ELAN Pharmaceuticals, LLC
    Inventors: Tamie Chilcote, Robin Barbour
  • Publication number: 20140050733
    Abstract: The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases.
    Type: Application
    Filed: February 7, 2012
    Publication date: February 20, 2014
    Inventors: Dale B. Schenk, Tarlochan S. Nijjar, Philip w. Payne, Robin Barbour
  • Publication number: 20130317199
    Abstract: The invention provides methods for detecting alpha-synuclein. The invention also identifies preferred epitopes of alpha synuclein for use in such detection, and provides antibodies specifically binding to such epitopes.
    Type: Application
    Filed: March 18, 2011
    Publication date: November 28, 2013
    Applicant: ELAN PHARMACEUTICALS, INC.
    Inventors: TAMIE CHILCOTE, ROBIN BARBOUR
  • Publication number: 20120258041
    Abstract: The invention provides antibodies that preferentially bind to iC3b relative to C3b. These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of diseases associated with deposits of the fragment.
    Type: Application
    Filed: April 6, 2012
    Publication date: October 11, 2012
    Inventors: Guriqbal S. Basi, Robin Barbour
  • Publication number: 20120204275
    Abstract: The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases.
    Type: Application
    Filed: February 7, 2012
    Publication date: August 9, 2012
    Applicant: Neotope Biosciences Limited
    Inventors: Dale B. Schenk, Tarlochan S. Nijjar, Philip W. Payne, Robin Barbour
  • Patent number: 7910333
    Abstract: The invention provides methods for detecting alpha-synuclein. The invention also identifies preferred epitopes of alpha synuclein for use in such detection, and provides antibodies specifically binding to such epitopes.
    Type: Grant
    Filed: January 27, 2010
    Date of Patent: March 22, 2011
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Tamie Chilcote, Robin Barbour
  • Patent number: 7811769
    Abstract: This invention provides methods useful in aiding in the diagnosis of Alzheimer's disease. The methods involve measuring the amount of amyloid-? peptide (x??41) in the cerebrospinal fluid of a patient. High levels of the peptide generally are inconsistent with a diagnosis of Alzheimer's. Low levels of the peptide are consistent with the disease and, with other tests, can provide a positive diagnosis. Other methods involve measuring the amounts of both A?(x??41) and tau. Low levels of A?(x??41) and high levels of tau are a positive indicator of Alzheimer's disease, while high levels of A?(x??41) and low levels of tau are a negative indication of Alzheimer's disease.
    Type: Grant
    Filed: June 28, 2004
    Date of Patent: October 12, 2010
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Peter A. Seubert, Carmen Vigo-Pelfrey, Dale B. Schenk, Robin Barbour
  • Publication number: 20100203631
    Abstract: The invention provides methods for detecting alpha-synuclein. The invention also identifies preferred epitopes of alpha synuclein for use in such detection, and provides antibodies specifically binding to such epitopes.
    Type: Application
    Filed: January 27, 2010
    Publication date: August 12, 2010
    Applicant: Elan Pharmaceuticals, Inc.
    Inventors: Tamie Chilcote, Robin Barbour